Page last updated: 2024-11-02

pioglitazone and Vitiligo

pioglitazone has been researched along with Vitiligo in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Vitiligo: A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.

Research Excerpts

ExcerptRelevanceReference
"Vitiligo is a complex disease wherein derangements in multiple pathways determine the loss of functional melanocytes."1.72A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist. ( Bellei, B; Caputo, S; Cigliana, G; D'Arino, A; Iacovelli, P; Migliano, E; Ottaviani, M; Pacifico, A; Papaccio, F; Picardo, M; Sciuto, L; Truglio, M, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Papaccio, F3
Bellei, B3
Ottaviani, M3
D'Arino, A3
Truglio, M3
Caputo, S3
Cigliana, G3
Sciuto, L3
Migliano, E3
Pacifico, A3
Iacovelli, P3
Picardo, M3

Other Studies

1 other study available for pioglitazone and Vitiligo

ArticleYear
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
    Cells, 2022, 11-12, Volume: 11, Issue:22

    Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo

2022
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
    Cells, 2022, 11-12, Volume: 11, Issue:22

    Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo

2022
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
    Cells, 2022, 11-12, Volume: 11, Issue:22

    Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo

2022
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
    Cells, 2022, 11-12, Volume: 11, Issue:22

    Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo

2022
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
    Cells, 2022, 11-12, Volume: 11, Issue:22

    Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo

2022
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
    Cells, 2022, 11-12, Volume: 11, Issue:22

    Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo

2022
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
    Cells, 2022, 11-12, Volume: 11, Issue:22

    Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo

2022
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
    Cells, 2022, 11-12, Volume: 11, Issue:22

    Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo

2022
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
    Cells, 2022, 11-12, Volume: 11, Issue:22

    Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo

2022